Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use MAXALT and MAXALT-MLT safely and effectively. See full prescribing information for MAXALT and MAXALT-MLT. MAXALT® (rizatriptan benzoate) tablets, for oral useMAXALT-MLT® (rizatriptan benzoate) orally disintegrating tabletsInitial U.S. Approval: 1998
Medication labelWhy this: Advisory · dailymed-prescription
MAXALT® and MAXALT-MLT® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster headache.
- generic_name
- rizatriptan benzoate
- product_names
- rizatriptan benzoate
- ndc
- 78206-142, 78206-142-99, 78206-142-01, 78206-143, 78206-143-99, 78206-143-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en